Prognostic implications of receptor discordance between primary and recurrent breast cancer

Matsumoto, Akiko; Jinno, Hiromitsu; Murata, Takeshi; Seki, Tomoko; Takahashi, Maiko; Hayashida, Tetsu; Kameyama, Kaori; Kitagawa, Yuukou

doi:10.1007/s10147-014-0759-2

Cited by 27 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason behind the decreased ER expression of BC#1 was surmised as follows. It has been reported that the hormone receptor discordance between primary and recurrent BC has occurred at the frequency of 10–40%, because of the change in tumor characteristics after treatment . In addition, it is known that long‐term estrogen deprivation in culture causes the instability of ER expression in vitro .…”

Section: Resultsmentioning

confidence: 99%

“…It has been reported that the hormone receptor discordance between primary and recurrent BC has occurred at the frequency of 10-40%, because of the change in tumor characteristics after treatment. (38) In addition, it is known that longterm estrogen deprivation in culture causes the instability of ER expression in vitro. (39) These factors might cause the discrepancy of the ER expression in BC#1 cells isolated from the pleural effusion.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations

et al. 2016

View full text Add to dashboard Cite

The expression of estrogen receptor is the key in most breast cancers (BC) and binding of estrogen receptor to the genome correlates to Forkhead protein (FOXA1) expression. We herein assessed the correlation between the cancer stem cell (CSC) population and FOXA1 expression in luminal BC. We established luminal BC cells derived from metastatic pleural effusion and analyzed the potency of CSC and related factors with established luminal BC cell lines. We also confirmed that mammosphere cultures have an increased aldehyde dehydrogenase‐positive population, which is one of the CSC markers, compared with adherent culture cells. Using a quantitative PCR analysis, we found that mammosphere forming cells showed a higher expression of FOXA1 and stemness‐related genes compared with adherent culture cells. Furthermore, the growth activity and colony‐forming activity of 4‐hydroxytamoxifen‐treated BC cells were inhibited in a mammosphere assay. Interestingly, 4‐hydroxytamoxifen‐resistant cells had significantly increased FOXA1 gene expression levels. Finally, we established short hairpin RNA of FOXA1 (shFOXA1) MCF‐7 cells and investigated the relationship between self‐renewal potential and FOXA1 expression. As a result, we found no significant difference in the number of mammospheres but decreased colony formation in shFOXA1 MCF‐7 cells compared with control. These results suggest that the expression of FOXA1 appears to be involved in the proliferation of immature BC cells rather than the induction of stemness‐related genes and self‐renewal potency of CSCs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations

et al. 2016

View full text Add to dashboard Cite

show abstract

“…According to studies on ER, PgR, and HER2 discordance between the primary focus and metastatic foci, the discordance rate has been reported as 10–18% for ER, 25–40% for PgR [10, 13, 14], and 3–24% for HER2 [10, 13, 14, 15]. In 14–64% of these cases, the treatment strategy was modified based on the discordance [13, 14, 15].…”

Section: Discussionmentioning

confidence: 99%

“…In 14–64% of these cases, the treatment strategy was modified based on the discordance [13, 14, 15]. …”

Section: Discussionmentioning

confidence: 99%

HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient was referred to our hospital for tests. Based on computed tomography, intrahepatic bile duct cancer or metastatic hepatic tumors were suspected, and a liver biopsy was performed. The histopathological diagnosis was a poorly differentiated adenocarcinoma (ER negative, PgR negative and HER2 positive), and the distinction from poorly differentiated intrahepatic bile duct cancer was difficult. Fluorodeoxyglucose (FDG)-positron emission tomography revealed FDG accumulation in the patient’s bones and soft tissues, in addition to the hepatic tumors. The patterns and finding of metastasis were compatible with breast cancer recurrence, and the patient was diagnosed with postoperative recurrence of left breast cancer. Pertuzumab, trastuzumab, and docetaxel were started, and the therapeutic effect was assessed as a partial response. It was evident that in this case, the expression of hormone receptors and HER2 differed between the primary focus and the recurrence foci, and this contributed to the treatment strategy. Whenever possible, a biopsy should be performed for lesions that are suspected to be distal metastases.

show abstract

“…Tissue confirmation led to changes in treatment for 14.2% of patients (37). When we evaluated 55 patients who had undergone biopsies or resections of recurrent lesions, discordance rates for ER, PgR and HER2 status were 16.4, 30.9 and 10.2%, respectively (38). Some retrospective studies report an association between changes in receptor status and poor prognosis (39,40).…”

Section: Discordance In Biomarker Status Between Primary and Recurrenmentioning

confidence: 99%

Biological markers of invasive breast cancer

Matsumoto

Jinno

Ando³

et al. 2015

Jpn. J. Clin. Oncol.

Self Cite

View full text Add to dashboard Cite

Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made the molecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision-making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testing methodology to minimize inter-laboratory measurement variations is a remaining issue. Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would be more precise, and could enhance the clinical development of personalized therapy in breast cancer.

show abstract

Prognostic implications of receptor discordance between primary and recurrent breast cancer

Abstract: Discordance in receptor status between primary and recurrent breast cancers were seen in 10-30 %. A gain in HR status was significantly associated with better prognosis.

Cited by 27 publications

References 19 publications

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations

HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer

Biological markers of invasive breast cancer

Contact Info

Product

Resources

About